Turning Point Therapeutics, Inc. (TPTX)
| Market Cap | 6.24B |
| Revenue (ttm) | 25.00M |
| Net Income (ttm) | -130.88M |
| Shares Out | 42.19M |
| EPS (ttm) | -3.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $129.52 |
| Previous Close | $133.00 |
| Change ($) | -3.48 |
| Change (%) | -2.62% |
| Day's Open | 134.40 |
| Day's Range | 127.16 - 135.81 |
| Day's Volume | 273,682 |
| 52-Week Range | 32.02 - 136.99 |
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point's MET/SRC/CSF1R Inhibitor, in Greater China
TPTX has demonstrated solid competitive data for its lead asset. The company, after two rounds of dilution, is heavy with cash.
Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Planned for Presentation at Upcoming World Conference on Lung Cancer Updated Data from TRI...
In this article we present the list of Top 10 Healthcare Stocks for the Future. Click to skip ahead and see the Top 5 Healthcare Stocks for the Future .
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
SAN DIEGO, Oct. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of c...
Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib Two Additional Abstracts Selected for Poster Presentations of Preclinical D...
SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers o...
SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers o...
Preeminent Leaders in Cancer Signaling Pathways and Dysregulated Protein Kinases to Advise Company’s Early Pipeline Development Preeminent Leaders in Cancer Signaling Pathways and Dysregulated...
SAN DIEGO, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Turning Point Therapeutics (TPTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Turning Point Therapeutics (TPTX) delivered earnings and revenue surprises of 14.58% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead f...
SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
SAN DIEGO, July 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.
Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations in Preclinical Models Next Generation ALK Inhibitor Candidate, TPX-0131, Overcomes ALK Resistant Mutations ...
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...
SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...
Turning Point Therapeutics (NASDAQ: TPTX) shares are trading higher on Wednesday.
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2020 Results - Earnings Call Transcript
SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of ...
As of late, it has definitely been a great time to be an investor Turning Point Therapeutics
Turning Point Therapeutics (TPTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
SAN DIEGO, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.
Turning Point Therapeutics CEO on the company's successful IPO
Dr. Athena Countouriotis, CEO of Turning Point Therapeutics, joins "Squawk Box" to discuss the succes of the company's IPO and what she expects going forward.
Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today annou...
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
SAN DIEGO, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today annou...
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2019 Results - Earnings Call Transcript
How Turning Point Therapeutics became a 2019 IPO standout
Turning Point Therapeutics is one of the 2019's IPO's that has been performing better than its cohorts, jumping 23% since its IPO.
About TPTX
Turning Point Therapeutics, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced s... [Read more...]
| Industry Biotechnology | IPO Date Apr 17, 2019 |
| CEO Dr. Athena Maria Countouriotis | Employees 130 |
| Stock Exchange NASDAQ | Ticker Symbol TPTX |
Analyst Forecasts
According to 10 analysts, the average rating for TPTX stock is "Strong Buy." The 12-month stock price forecast is 147.40, which is an increase of 13.80% from the latest price.